Enovis Corporation (ENOV) - 10-K Summary
Business Context and Reporting Period
Company: Enovis Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Enovis is a medical technology company operating through two segments: Prevention & Recovery (P&R) (orthopedic bracing, rehabilitation, pain management) and Reconstructive (Recon) (surgical implants for joint replacement). The company utilizes the "Enovis Growth Excellence" (EGX) business system to drive continuous improvement. In 2025, the company completed seven small acquisitions and divested its Dr. Comfort Footcare Solutions U.S. operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Net Sales | $2,248.0 | $2,107.6 |
| Gross Profit | $1,345.3 | $1,180.8 |
| Gross Margin | 59.8% | 56.0% |
| Operating Loss (GAAP) | $(1,124.2) | $(775.7) |
| Net Loss (GAAP) | $(1,183.6) | $(824.8) |
| Adjusted EBITDA (Non-GAAP) | $403.0 | $376.5 |
| Adjusted EBITDA Margin | 17.9% | 17.9% |
| Cash from Operating Activities | $217.3 | $113.5 |
| Total Debt Outstanding | $1,296.8 | $1,329.5 |
| Cash and Cash Equivalents | $36.4 | $48.2 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.7% to $2.25 billion, driven by a $123.5 million increase in existing business sales and favorable foreign currency translation ($30.0 million), partially offset by the divestiture of Dr. Comfort.
- Goodwill Impairment: The company recognized a massive non-cash goodwill impairment charge of $1.05 billion in 2025 (up from $645.0 million in 2024). This was triggered by a sustained decrease in the company's share price and market capitalization relative to the carrying value of its reporting units. Charges were split between P&R ($387.8 million) and Recon ($662.0 million).
- Profitability: While GAAP Net Loss widened significantly due to impairment charges, Adjusted EBITDA grew 7.0% to $403.0 million, reflecting underlying operational strength and improved gross margins (up 380 basis points).
- Acquisitions & Divestitures: Completed seven acquisitions totaling $36.9 million in 2025. Divested Dr. Comfort Footcare Solutions for net proceeds of $43.3 million.
- Debt Structure: In December 2025, the company amended its Credit Agreement, increasing the Revolver capacity to $1.1 billion and the Term Loan to $700 million, extending maturities to 2030.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management continues to focus on organic growth and strategic acquisitions. The company expects to maintain compliance with financial covenants (Senior Secured Leverage Ratio max 3.50:1.00).
- Unusual Items:
- Goodwill Impairment: $1.05 billion non-cash charge significantly impacted GAAP results but does not affect cash flow.
- Purchase of Royalty Interest: A $45.8 million charge was recorded to buyout future royalty payments on legacy products.
- Strategic Transaction Costs: $60.4 million incurred, primarily related to the integration of the Lima Acquisition and other M&A activities.
- Risks:
- Regulatory: Extensive oversight by the FDA and EU Medical Device Regulation (MDR) compliance costs ($9.8 million in 2025).
- Geopolitical: Exposure to global conflicts (Russia/Ukraine, Middle East) and potential tariffs impacting raw material costs.
- SEC Comments: The company has unresolved comments from the SEC Staff regarding the treatment of certain non-GAAP adjustments (royalty interest and inventory step-up charges).
- Cybersecurity: The company experienced a cybersecurity incident in 2025 involving a third-party cloud provider, though no material impact was reported.
Key Facts for Investor Verification
- Goodwill Valuation: Verify the assumptions used in the quantitative goodwill impairment tests (discount rates, market multiples, cash flow projections) given the $1.7 billion accumulated impairment loss.
- SEC Non-GAAP Dispute: Monitor the resolution of the SEC Staff's comments regarding the exclusion of royalty interest and inventory step-up charges from Adjusted EBITDA.
- Debt Covenants: Confirm ongoing compliance with the Senior Secured Leverage Ratio covenant, especially given the recent debt refinancing and high leverage levels.
- Integration of Lima: Assess the realization of synergies from the 2024 Lima Acquisition, which continues to drive significant integration costs.
- Regulatory Compliance: Track progress on EU MDR certification for legacy devices, as failure to comply could restrict market access in Europe.